PremiumThe FlyPTC Therapeutics price target lowered to $75 from $78 at JPMorgan Cautious Hold Rating on PTC Therapeutics Amid Regulatory Challenges and Pipeline Developments Strategic Resilience and Growth Potential: A Buy Rating for PTC Therapeutics Amid Regulatory Challenges PremiumThe FlyPTC Therapeutics presents new data from Phase 3 APHENITY trial JPMorgan ups PTC Therapeutics target, adds to Focus List PTC Therapeutics price target raised to $50 from $46 at Citi PremiumCompany AnnouncementsPTC Therapeutics’ Earnings Call: Strong 2024 Amid Challenges Promising Growth and Financial Stability Make PTC Therapeutics a Strong Buy PTC Therapeutics Faces Regulatory and Revenue Challenges: Analyst Maintains Sell Rating 
